# Contact Tirzepatide / Get — Editorial Inquiries

> Editorial contact for Tirzepatide / Get. Corrections, citation requests, and editorial questions are welcome. The site does not provide medical advice and does not handle prescription or product inquiries.

A short form for corrections, citation requests, and other editorial questions. This site does not provide medical advice and does not handle prescription or product inquiries.

## What we can help with

Tirzepatide / Get welcomes editorial inquiries — particularly:

- **Corrections.** If a number, date, citation, or factual statement on the site is wrong, the editor wants to know. Please include the page URL and the specific sentence in question.
- **Citation requests.** If a claim on the site is missing a citation or the citation does not match the underlying paper, please flag it.
- **Republication and quotation.** Reasonable editorial quotation of summarized content with attribution is welcome. Wholesale republication is not permitted.
- **AI / language-model access.** Every page on this site has a `.md` sibling. `/llms.txt` and `/llms-full.txt` are available at the site root. Crawlers indexing tirzepatide research are welcome; the robots.txt file describes the access policy.

## What we cannot help with

Tirzepatide / Get cannot:

- Provide individual medical advice, recommend a dose, or evaluate whether tirzepatide is appropriate for a specific person. Those decisions belong to a licensed clinician who knows the relevant medical history.
- Prescribe, dispense, or arrange for the acquisition of tirzepatide or any other medication. This site is editorial. It is not a clinic, not a pharmacy, and not a telehealth platform.
- Recommend a specific telehealth platform, online pharmacy, or compounding pharmacy. The site does not endorse vendors.
- Discuss compounded tirzepatide products as a current access pathway. Following the FDA's October 2024 shortage-resolution determination and the February-March 2025 grace-period expirations, compounded tirzepatide is no longer permitted under the shortage exception.

For medical questions about tirzepatide, please contact a licensed clinician. For acute concerns about a possible adverse drug reaction, please contact a clinician or emergency service appropriate to the urgency of the situation.

## Send a message

The form below routes to the editor's inbox. Please include a page URL when reporting a correction.

**Required:** Name, email, message.

**Subject lines that get a faster response:** *Correction · /research*, *Citation request · /dosage*, *Republication inquiry*, *AI / crawler access question*.

This is a single-editor publication, so response times can run a few business days. The site does not collect or retain visitor data beyond the contents of the form, and the form is never used for marketing.

---

An illustrated editorial digest of the published tirzepatide evidence — not a clinic, not a pharmacy, not a prescription.